Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GeneDx Holdings Corp.WGS · Entity 1634 | Director | June 18, 2026 | June 23, 2026 |
| Twist Bioscience CorpTWST · Entity 3619 | Director · Chief Executive Officer | October 05, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GeneDx Holdings Corp.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 24,852 |
Reported balance
After 2026-06-18 transaction · row 1
1 source rowRow 1 · 2026-06-18 · Exercise / conversion · Acquired 3,576 · Balance 24,852 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 4,248 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 4,248 · Balance 4,248 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2: The entire award shall vest on the earlier of the (i) date of the 2027 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-18 · Exercise / conversion · Disposed 3,576 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3: The entire award vested or vests on the earlier of the: (i) date of the 2026 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F2: The entire award shall vest on the earlier of the (i) date of the 2027 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.
F3: The entire award vested or vests on the earlier of the: (i) date of the 2026 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.
Twist Bioscience Corp
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 562,760 |
Ending reported balance
After 2026-10-05 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2026-10-05 · Sale · Disposed 1,840 · Balance 565,468 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F2: Represents the weighted average sales price per share. The shares sold at prices ranging from $200 to $200.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 2 · 2026-10-05 · Sale · Disposed 481 · Balance 564,987 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F3: Represents the weighted average sales price per share. The shares sold at prices ranging from $201 to $201.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 3 · 2026-10-05 · Sale · Disposed 1,017 · Balance 563,970 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F4: Represents the weighted average sales price per share. The shares sold at prices ranging from $202 to $202.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 4 · 2026-10-05 · Sale · Disposed 432 · Balance 563,538 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F5: Represents the weighted average sales price per share. The shares sold at prices ranging from $203.29 to $203.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 5 · 2026-10-05 · Sale · Disposed 290 · Balance 563,248 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F6: Represents the weighted average sales price per share. The shares sold at prices ranging from $204.33 to $205.32 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 6 · 2026-10-05 · Sale · Disposed 297 · Balance 562,951 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F7: Represents the weighted average sales price per share. The shares sold at prices ranging from $205.37 to $206.34 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 7 · 2026-10-05 · Sale · Disposed 146 · Balance 562,805 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F8: Represents the weighted average sales price per share. The shares sold at prices ranging from $206.38 to $207.33 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 8 · 2026-10-05 · Sale · Disposed 45 · Balance 562,760 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F9: Represents the weighted average sales price per share. The shares sold at prices ranging from $207.38 to $207.8 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.33 · Expires 2029-10-23 | Direct | 131,290 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 131,290 F10: 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.85 · Expires 2030-08-31 | Direct | 64,950 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 64,950 F11: Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026.
F2: Represents the weighted average sales price per share. The shares sold at prices ranging from $200 to $200.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3: Represents the weighted average sales price per share. The shares sold at prices ranging from $201 to $201.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F4: Represents the weighted average sales price per share. The shares sold at prices ranging from $202 to $202.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F5: Represents the weighted average sales price per share. The shares sold at prices ranging from $203.29 to $203.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F6: Represents the weighted average sales price per share. The shares sold at prices ranging from $204.33 to $205.32 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F7: Represents the weighted average sales price per share. The shares sold at prices ranging from $205.37 to $206.34 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F8: Represents the weighted average sales price per share. The shares sold at prices ranging from $206.38 to $207.33 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F9: Represents the weighted average sales price per share. The shares sold at prices ranging from $207.38 to $207.8 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F10: 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
F11: Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2021 Filed Oct 6, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | GiftCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-010286 · marketforms-53986.xml · nonDerivative · entry 6 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,143 Read SEC document |
| September 15, 2021 Filed Oct 6, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | GiftCommon Stock | 1,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-010286 · marketforms-53986.xml · nonDerivative · entry 5 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,143 Read SEC document |
| September 15, 2021 Filed Oct 6, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | GiftCommon Stock | 1,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-010286 · marketforms-53986.xml · nonDerivative · entry 4 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,343 Read SEC document |
| September 15, 2021 Filed Oct 6, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | GiftCommon Stock | 1,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-010286 · marketforms-53986.xml · nonDerivative · entry 3 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,543 Read SEC document |
| September 15, 2021 Filed Oct 6, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | GiftCommon Stock | 1,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-010286 · marketforms-53986.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,743 Read SEC document |
| September 15, 2021 Filed Oct 6, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | GiftCommon Stock | 1,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-010286 · marketforms-53986.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,943 Read SEC document |
| September 10, 2021 Filed Sep 13, 2021 22:40 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 13,920 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001214659-21-009462 · marketforms-53800.xml · derivative · entry 12 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,693 Underlying: Common Stock · 13,920 shares Expires 2025-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| September 10, 2021 Filed Sep 13, 2021 22:40 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 3,480 | $120.14 | $418,091.72 |
DisclosureSEC source: 0001214659-21-009462 · marketforms-53800.xml · nonDerivative · entry 7 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,143 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F6 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $120.00 to $120.75 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 10, 2021 Filed Sep 13, 2021 22:40 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 647 | $118.41 | $76,612.18 |
DisclosureSEC source: 0001214659-21-009462 · marketforms-53800.xml · nonDerivative · entry 6 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,623 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $118.36 to $118.44 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 10, 2021 Filed Sep 13, 2021 22:40 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 3,462 | $117.78 | $407,768.55 |
DisclosureSEC source: 0001214659-21-009462 · marketforms-53800.xml · nonDerivative · entry 5 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,270 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $117.32 to $118.31 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 10, 2021 Filed Sep 13, 2021 22:40 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 6,331 | $116.92 | $740,229.38 |
DisclosureSEC source: 0001214659-21-009462 · marketforms-53800.xml · nonDerivative · entry 4 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,732 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $116.32 to $117.27 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 10, 2021 Filed Sep 13, 2021 22:40 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 13,920 | $5.95 | $82,824.00 |
DisclosureSEC source: 0001214659-21-009462 · marketforms-53800.xml · nonDerivative · entry 3 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 22:40 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 15,667 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-21-009462 · marketforms-53800.xml · derivative · entry 11 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,672 Underlying: Common Stock · 15,667 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 22:40 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 15,667 | $119.04 | $1,864,943.28 |
DisclosureSEC source: 0001214659-21-009462 · marketforms-53800.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,143 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $118.75 to $119.72 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 22:40 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 15,667 | $8.82 | $138,182.94 |
DisclosureSEC source: 0001214659-21-009462 · marketforms-53800.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,810 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 419 | $116.16 | $48,670.50 |
DisclosureSEC source: 0001214659-21-009309 · marketforms-53722.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,143 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $116.09 to $116.22 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 5,910 | $115.43 | $682,173.57 |
DisclosureSEC source: 0001214659-21-009309 · marketforms-53722.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,562 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $115.00 to $115.89 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 31, 2021 Filed Sep 1, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 28,455 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-21-009247 · marketforms-53695.xml · derivative · entry 19 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,339 Underlying: Common Stock · 28,455 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F16 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| August 31, 2021 Filed Sep 1, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,556 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001214659-21-009247 · marketforms-53695.xml · derivative · entry 18 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,613 Underlying: Common Stock · 1,556 shares Expires 2025-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F15 · derivative.exercise_date: The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| August 31, 2021 Filed Sep 1, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 906 | $110.49 | $100,103.12 |
DisclosureSEC source: 0001214659-21-009247 · marketforms-53695.xml · nonDerivative · entry 14 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,472 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F12 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $110.34 to $110.68 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 31, 2021 Filed Sep 1, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 4,677 | $109.66 | $512,899.46 |
DisclosureSEC source: 0001214659-21-009247 · marketforms-53695.xml · nonDerivative · entry 13 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,378 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F11 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $109.33 to $110.19 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 31, 2021 Filed Sep 1, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 24,428 | $108.92 | $2,660,683.10 |
DisclosureSEC source: 0001214659-21-009247 · marketforms-53695.xml · nonDerivative · entry 12 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,055 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F10 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $108.33 to $109.32 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 31, 2021 Filed Sep 1, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 28,455 | $8.82 | $250,973.10 |
DisclosureSEC source: 0001214659-21-009247 · marketforms-53695.xml · nonDerivative · entry 11 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2021 Filed Sep 1, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 1,556 | $5.95 | $9,258.20 |
DisclosureSEC source: 0001214659-21-009247 · marketforms-53695.xml · nonDerivative · entry 10 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,028 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 9,530 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001214659-21-009247 · marketforms-53695.xml · derivative · entry 17 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,169 Underlying: Common Stock · 9,530 shares Expires 2025-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F15 · derivative.exercise_date: The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,300 | $110.48 | $143,626.99 |
DisclosureSEC source: 0001214659-21-009247 · marketforms-53695.xml · nonDerivative · entry 9 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,472 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F9 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $110.30 to $111.07 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 4,530 | $109.45 | $495,815.75 |
DisclosureSEC source: 0001214659-21-009247 · marketforms-53695.xml · nonDerivative · entry 8 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,772 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F8 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $109.10 to $110.05 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 3,700 | $108.77 | $402,437.90 |
DisclosureSEC source: 0001214659-21-009247 · marketforms-53695.xml · nonDerivative · entry 7 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,302 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F7 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $108.07 to $109.06 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 9,530 | $5.95 | $56,703.50 |
DisclosureSEC source: 0001214659-21-009247 · marketforms-53695.xml · nonDerivative · entry 6 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,002 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,000 | $110.08 | $220,159.00 |
DisclosureSEC source: 0001214659-21-009247 · marketforms-53695.xml · nonDerivative · entry 5 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,472 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F6 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $109.72 to $110.38 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 7,905 | $109.15 | $862,831.54 |
DisclosureSEC source: 0001214659-21-009247 · marketforms-53695.xml · nonDerivative · entry 4 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,472 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $108.68 to $109.64 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 9,654 | $108.09 | $1,043,516.31 |
DisclosureSEC source: 0001214659-21-009247 · marketforms-53695.xml · nonDerivative · entry 3 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,377 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $107.68 to $108.67 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 3,173 | $107.18 | $340,085.95 |
DisclosureSEC source: 0001214659-21-009247 · marketforms-53695.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,031 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $106.59 to $107.58 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,400 | $105.78 | $148,091.02 |
DisclosureSEC source: 0001214659-21-009247 · marketforms-53695.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,204 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $105.57 to $106.08 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 20:31 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 2,870 | $100.49 | $288,406.30 |
DisclosureSEC source: 0001214659-21-008950 · marketforms-53634.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,604 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). F2 · balance_after: Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 200 | $123.54 | $24,708.00 |
DisclosureSEC source: 0001214659-21-008149 · marketforms-53508.xml · nonDerivative · entry 4 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,412 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 16, 2020. F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $123.32 to $123.76 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 400 | $121.09 | $48,436.80 |
DisclosureSEC source: 0001214659-21-008149 · marketforms-53508.xml · nonDerivative · entry 3 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,612 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 16, 2020. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $120.88 to $121.44 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,000 | $120.21 | $120,212.60 |
DisclosureSEC source: 0001214659-21-008149 · marketforms-53508.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,012 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 16, 2020. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $119.75 to $120.56 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 400 | $119.03 | $47,613.64 |
DisclosureSEC source: 0001214659-21-008149 · marketforms-53508.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,012 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 16, 2020. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $118.51 to $119.18 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| July 23, 2021 Filed Jul 27, 2021 21:01 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 944 | $117.34 | $110,768.96 |
DisclosureSEC source: 0001214659-21-007872 · marketforms-53385.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,412 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| July 22, 2021 Filed Jul 26, 2021 22:48 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantPrivate Placement Warrants · Derivative | 166,666 | $11.50 Strike: $11.50 | $1,916,659.00 |
DisclosureSEC source: 0001209191-21-048227 · doc4.xml · derivative · entry 3 Leproust Emily M. · CIK 0001753655 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,666 Underlying: Class A Common Stock · 166,666 shares Expires not disclosed F2 · kind: In connection with the consummation of the Business Combination, all of the private placement warrants of CMLS held by the Reporting Person, which previously entitled the Reporting Person to purchase one share of CMLS's Class A Common Stock at a price of $11.50 per whole share at any time commencing on the later of 12 months from the closing of CMLS's initial public offering or 30 days after the completion of an initial business combination of CMLS, were converted into private placement warrants of Issuer (each a "New Private Placement Warrant") simultaneously with the closing of the Business Combination, with each whole New Private Placement Warrant entitling the holder thereof to the right to purchase one share of Issuer's Class A Common Stock. F2 · derivative.exercise_date: In connection with the consummation of the Business Combination, all of the private placement warrants of CMLS held by the Reporting Person, which previously entitled the Reporting Person to purchase one share of CMLS's Class A Common Stock at a price of $11.50 per whole share at any time commencing on the later of 12 months from the closing of CMLS's initial public offering or 30 days after the completion of an initial business combination of CMLS, were converted into private placement warrants of Issuer (each a "New Private Placement Warrant") simultaneously with the closing of the Business Combination, with each whole New Private Placement Warrant entitling the holder thereof to the right to purchase one share of Issuer's Class A Common Stock. F2 · derivative.expiration_date: In connection with the consummation of the Business Combination, all of the private placement warrants of CMLS held by the Reporting Person, which previously entitled the Reporting Person to purchase one share of CMLS's Class A Common Stock at a price of $11.50 per whole share at any time commencing on the later of 12 months from the closing of CMLS's initial public offering or 30 days after the completion of an initial business combination of CMLS, were converted into private placement warrants of Issuer (each a "New Private Placement Warrant") simultaneously with the closing of the Business Combination, with each whole New Private Placement Warrant entitling the holder thereof to the right to purchase one share of Issuer's Class A Common Stock. Read SEC document |
| July 22, 2021 Filed Jul 26, 2021 22:48 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | ConversionClass B Common Stock · Derivative | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-048227 · doc4.xml · derivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences, Inc. or "CMLS") and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), among other things, each share of CMLS's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis. F1 · kind: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences, Inc. or "CMLS") and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), among other things, each share of CMLS's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis. F1 · price: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences, Inc. or "CMLS") and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), among other things, each share of CMLS's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis. F1 · derivative.exercise_date: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences, Inc. or "CMLS") and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), among other things, each share of CMLS's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis. F1 · derivative.expiration_date: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences, Inc. or "CMLS") and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), among other things, each share of CMLS's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis. Read SEC document |
| July 22, 2021 Filed Jul 26, 2021 22:48 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | ConversionClass A Common Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-048227 · doc4.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences, Inc. or "CMLS") and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), among other things, each share of CMLS's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 100 | $129.99 | $12,999.00 |
DisclosureSEC source: 0001214659-21-007499 · marketforms-53383.xml · nonDerivative · entry 4 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,356 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 16, 2020. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 200 | $129.13 | $25,825.00 |
DisclosureSEC source: 0001214659-21-007499 · marketforms-53383.xml · nonDerivative · entry 3 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,456 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 16, 2020. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $128.66 to $129.59 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 900 | $125.62 | $113,059.53 |
DisclosureSEC source: 0001214659-21-007499 · marketforms-53383.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,656 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 16, 2020. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $125.34 to $125.90 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 800 | $124.77 | $99,819.52 |
DisclosureSEC source: 0001214659-21-007499 · marketforms-53383.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,556 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 16, 2020. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $124.28 to $125.12 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 23:33 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 630 | $131.48 | $82,832.40 |
DisclosureSEC source: 0001214659-21-007318 · marketforms-53259.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,356 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 21:20 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 400 | $116.12 | $46,448.00 |
DisclosureSEC source: 0001214659-21-006635 · marketforms-53144.xml · nonDerivative · entry 3 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,986 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 16, 2020. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $115.70 to $116.56 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 21:20 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 500 | $113.30 | $56,651.30 |
DisclosureSEC source: 0001214659-21-006635 · marketforms-53144.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,386 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 16, 2020. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $113.05 to $113.55 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.